Therapy Areas: Infectious Diseases
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
19 November 2026 -

Akagera Medicines Inc, a clinical-stage biopharmaceutical company developing lipid nanoparticle (LNP) therapeutics and vaccines for infectious diseases, announced on Wednesday that the Gates Foundation has expanded its grant supporting the company's dendritic cell-targeted LNP mRNA vaccine for the prevention of tuberculosis (TB).

This award adds USD7,806,414 in funding, bringing the total committed under the grant to USD9,791,826.

The grant continues a preclinical feasibility and development programme first funded in 2023. The expanded funding will support GMP manufacturing of clinical trial material and the IND-enabling toxicology studies ahead of a future regulatory filing and before a first-in-human (FIH) Phase 1 clinical trial.

Akagera's vaccine candidate pairs mRNA-encoded Mycobacterium tuberculosis antigens with an LNP engineered to preferentially deliver its payload to dendritic cells, the immune system's most potent antigen-presenting cells. By directing antigen expression to these cells, the approach is designed to drive the strong, durable T-cell responses believed to be central to protection against TB, while potentially enabling lower doses and improved tolerability.

Login
Username:

Password: